IOBT Insider Trading
Insider Ownership Percentage: 2.30%
Insider Buying (Last 12 Months): $20,850.00
Insider Selling (Last 12 Months): $0.00
IO Biotech Share Price & Price History
Current Price: $0.05
Price Change: +0.30 (1.20%)
As of 04/7/2026 01:00 AM ET
IO Biotech Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/30/2025 | Heidi Hunter | Director | Buy | 15,000 | $1.39 | $20,850.00 | 15,000 | |
| 12/23/2024 | Amy Sullivan | CFO | Buy | 10,250 | $0.83 | $8,507.50 | 84,632 | |
| 12/23/2024 | Mai-Britt Zocca | CEO | Buy | 12,500 | $0.81 | $10,125.00 | 49,891 | |
| 7/25/2024 | Holdings A/S Novo | Major Shareholder | Sell | 51,522 | $1.33 | $68,524.26 | 4,377,927 | |
| 5/10/2024 | Holdings A/S Novo | Major Shareholder | Sell | 658,809 | $1.22 | $803,746.98 | 4,429,449 | |
| 2/9/2024 | Holdings A/S Novo | Major Shareholder | Sell | 658,809 | $1.50 | $988,213.50 | 5,088,258 | |
| 11/21/2023 | Brian Burkavage | CAO | Buy | 5,000 | $0.99 | $4,950.00 | 6,500 | |
| 8/9/2023 | Vivo Capital Ix, Llc | Major Shareholder | Buy | 3,157,894 | $1.90 | $5,999,998.60 | 3,157,894 | |
IO Biotech Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 2/18/2026 | Beacon Pointe Advisors LLC | 506,000 | $0.31M | 0.0% | N/A | 0.703% |  |
| 2/18/2026 | Ikarian Capital LLC | 1,386,565 | $0.84M | 0.1% | -9.1% | 1.927% |  |
| 2/18/2026 | Millennium Management LLC | 138,716 | $84K | 0.0% | -90.0% | 0.193% |  |
| 2/18/2026 | Boothbay Fund Management LLC | 451,852 | $0.28M | 0.0% | -23.6% | 0.628% |  |
| 2/13/2026 | Marshall Wace LLP | 429,338 | $0.26M | 0.0% | -59.2% | 0.597% |  |
| 2/12/2026 | Renaissance Technologies LLC | 207,601 | $0.13M | 0.0% | -62.1% | 0.289% |  |
| 11/17/2025 | Novo Holdings A S | 2,512,453 | $0.91M | 0.1% | -25.1% | 3.814% |  |
| 11/17/2025 | Millennium Management LLC | 1,392,396 | $0.51M | 0.0% | N/A | 2.114% |  |
| 11/17/2025 | Bank of America Corp DE | 799,953 | $0.29M | 0.0% | -50.5% | 1.214% |  |
| 11/17/2025 | Boothbay Fund Management LLC | 591,180 | $0.22M | 0.0% | N/A | 0.897% |  |
| 8/19/2025 | Marex Group plc | 45,000 | $63K | 0.0% | N/A | 0.000% |  |
| 8/15/2025 | Bank of America Corp DE | 1,615,074 | $2.25M | 0.0% | -2.2% | 0.000% |  |
| 8/14/2025 | NewEdge Advisors LLC | 24,217 | $34K | 0.0% | N/A | 0.037% |  |
| 8/12/2025 | XTX Topco Ltd | 29,189 | $41K | 0.0% | -42.2% | 0.000% |  |
| 5/21/2025 | Acadian Asset Management LLC | 30,858 | $33K | 0.0% | -49.1% | 0.047% |  |
| 5/19/2025 | Jane Street Group LLC | 23,717 | $26K | 0.0% | N/A | 0.036% |  |
| 5/15/2025 | Landscape Capital Management L.L.C. | 400,234 | $0.44M | 0.0% | -9.5% | 0.608% |  |
| 5/8/2025 | XTX Topco Ltd | 50,486 | $55K | 0.0% | +80.0% | 0.077% |  |
| 5/7/2025 | Dauntless Investment Group LLC | 681,446 | $0.74M | 0.9% | -8.9% | 1.034% |  |
| 2/17/2025 | Bridgeway Capital Management LLC | 174,000 | $0.16M | 0.0% | -12.8% | 0.264% |  |
| 2/17/2025 | Citadel Advisors LLC | 270,504 | $0.25M | 0.0% | N/A | 0.411% |  |
| 2/14/2025 | Dauntless Investment Group LLC | 747,646 | $0.69M | 0.7% | N/A | 1.135% |  |
| 2/13/2025 | XTX Topco Ltd | 28,040 | $26K | 0.0% | N/A | 0.043% |  |
| 2/13/2025 | Renaissance Technologies LLC | 118,800 | $0.11M | 0.0% | +22.5% | 0.180% |  |
| 2/12/2025 | Landscape Capital Management L.L.C. | 442,196 | $0.41M | 0.0% | N/A | 0.671% |  |
| 1/30/2025 | Vontobel Holding Ltd. | 32,667 | $30K | 0.0% | N/A | 0.050% |  |
| 10/24/2024 | Novo Holdings A S | 3,354,449 | $3.52M | 0.2% | -24.3% | 5.092% |  |
| 8/20/2024 | Novo Holdings A S | 4,429,449 | $5.18M | 0.3% | -12.9% | 6.723% |  |
| 8/15/2024 | Armistice Capital LLC | 1,545,000 | $1.81M | 0.0% | -10.4% | 2.345% |  |
| 8/12/2024 | XTX Topco Ltd | 26,555 | $31K | 0.0% | +67.4% | 0.040% |  |
| 8/9/2024 | Renaissance Technologies LLC | 180,800 | $0.21M | 0.0% | +8.1% | 0.274% |  |
| 2/15/2024 | PFM Health Sciences LP | 2,341,107 | $4.40M | 0.3% | +73.0% | 3.554% |  |
| 2/13/2024 | Stonepine Capital Management LLC | 1,666,037 | $3.13M | 1.4% | -15.7% | 2.529% |  |
| 2/13/2024 | Armistice Capital LLC | 1,924,000 | $3.62M | 0.0% | -10.4% | 2.920% |  |
| 11/15/2023 | Armistice Capital LLC | 2,148,000 | $3.03M | 0.0% | N/A | 3.260% |  |
| 11/14/2023 | Stonepine Capital Management LLC | 1,975,308 | $2.79M | 0.9% | N/A | 2.998% |  |
| 11/14/2023 | Pivotal bioVenture Partners Investment Advisor LLC | 864,197 | $1.22M | 0.5% | N/A | 1.312% |  |
| 11/8/2023 | Vivo Capital LLC | 6,173,439 | $8.71M | 1.1% | +104.7% | 9.371% |  |
| 7/25/2023 | Summit Trail Advisors LLC | 43,744 | $86K | 0.0% | N/A | 0.152% |  |
| 2/14/2023 | RA Capital Management L.P. | 1,127,260 | $2.59M | 0.1% | -39.3% | 3.911% |  |
| 11/14/2022 | Psagot Value Holdings Ltd. Israel | 40,846 | $0.11M | 0.0% | N/A | 0.142% |  |
| 11/2/2022 | Victory Capital Management Inc. | 43,741 | $0.12M | 0.0% | N/A | 0.152% |  |
| 2/15/2022 | Samsara BioCapital LLC | 1,120,437 | $7.17M | 1.4% | N/A | 3.888% |  |
| 2/15/2022 | Capital World Investors | 1,235,000 | $8.11M | 0.0% | N/A | 4.286% |  |
| 2/14/2022 | Soleus Capital Management L.P. | 672,734 | $4.31M | 0.4% | N/A | 2.335% |  |
| 2/14/2022 | Novo Holdings A S | 3,277,932 | $20.98M | 1.0% | N/A | 11.376% |  |
Data available starting January 2016
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Read More on IO Biotech
Volume
N/A
Average Volume
9,043,608 shs
Market Capitalization
$3.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.88
Who are the company insiders with the largest holdings of IO Biotech?